Read or Download The Diabetes Market Outlook PDF
Similar medicine books
Now not easy line drawings on a web page, molecular buildings can now be considered in full-figured glory, frequently in colour or even with interactive percentages. Anatomy of Gene rules is the 1st publication to provide the elements and approaches of gene legislation on the third-dimensional point. shiny constructions of nucleic acids and their spouse proteins are printed in full-color, 3-dimensional shape.
- Embodiment, Morality, and Medicine
- Medicine: PreTest Self-Assessment and Review - 9th edition
- Practical Urodynamics for the Clinician
- New Research on Antioxidants (Nova Biomedical)
Extra info for The Diabetes Market Outlook
Example text
Clinical results so far have indicated a significant dose dependant reduction in HbA1c, both alone and as an additive to metformin therapy. MK-0431 (Merck): Merck expects to begin late stage trials in 2004 of MK-0431 and seek approval in mid-2006. It is expected that Merck’s drug will also cause weight loss in diabetics but the company has released less data than Novartis. 47 TLFeBOOK Amylinomimetic agents Symlin (pramlintide) is a synthetic version of the human hormone, amylin. It is the first (and currently only) member of a new class of therapeutic medications known as amylinomimetic agents, or amylin receptor agonists.
3%). 4 shows sales figures for each insulin class over the past five years. The long acting insulins have increased market share significantly with the launch of Aventis’ Lantus and now Novo Nordisk’s Levemir. The fast acting insulins also grew during this five-year period with the launch of Humalog and NovoLog, and in 2003 were the highest selling insulin class. The fast-acting insulin market and insulin devices market are also likely to grow significantly in the future with the development of oral and inhaled insulin formulations.
32 TLFeBOOK Introduction This chapter reviews the current and future growth drivers in the diabetes market, highlighting the therapies in development that will shape the market in the future. History of antidiabetic drugs Insulin is the oldest class of antidiabetic drug, and remains the only drug available for treating type I diabetics as these patients have the inability to produce insulin, and thus no breakdown of glucose occurs in the body without an external source of insulin. The sulfonylureas and biguanides (both OADs) became available in 1950 and 1958 respectively, before human insulin became the first recombinant DNA product on the market in the 1980s.
The Diabetes Market Outlook
by William
4.1